Sanofi gets binding bids for consumer unit
Banks and other lenders are readying over €10B ($11.1B) in funding as New York-based buyout firm Clayton Dubilier & Rice and ...
Sanofi named a new chief scientific officer this week, part of a series of moves aimed at redefining the company.
After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.
NEW YORK (Reuters) - Sanofi Chief Executive Paul Hudson said on Monday that the company has not made a final decision yet on ...
As Poland prepares for its EU Presidency, health needs to be a major focus, given its crucial role in Europe's prosperity and global competitiveness. Predictable pharmaceutical legislation is essentia ...
The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...
Sanofi said on Friday that its multiple sclerosis drug candidate was shown to delay worsening of a progressive form of the ...
1d
Analyst Eric Le Berrigaud from Stifel Nicolaus maintained a Buy rating on Sanofi (SNYNF – Research Report) and increased the price target ...
EADV: New data reinforce Sanofi’s innovative approach and leadership across immune-mediated skin diseases 24 abstracts for Dupixent, including 4 oral presentations, highlight impact of ...
The U.S. Food and Drug Administration said on Friday it has approved the use of a drug combination along with Sanofi's ...
Sanofi SA (NASDAQ:SNY) agreed to make a $27 million strategic investment in Ventyx Biosciences Inc (NASDAQ:VTYX). “We look ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback